Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
77 hedge funds and large institutions have $49.8M invested in Adverum Biotechnologies in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 13 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 82 → 77 (-5)
18.99% less ownership
Funds ownership: 57.14% → 38.14% (-19%)
38% less capital invested
Capital invested by funds: $80.1M → $49.8M (-$30.3M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $101K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.06M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.23M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.08M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$849K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$704K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.37M |
| 2 |
GCM
Gruss Capital Management
New York
|
-$1.34M |
| 3 |
WCM
Wildcat Capital Management
New York
|
-$995K |
| 4 |
Goldman Sachs
New York
|
-$653K |
| 5 |
Millennium Management
New York
|
-$591K |
ADVM Hedge Fund Activity: Q2 2016 in Review
77 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2016, worth a combined $49.8M — down 38% from $80.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ADVM and 8 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 37 added.
The largest buyer was Renaissance Technologies, adding an estimated $2.06M. The largest seller was Great Point Partners, cutting an estimated $3.37M.
- 77 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2016, down from 82 in Q1 2016.
- Funds reported $49.8M of Adverum Biotechnologies stock for Q2 2016, down 38% quarter-over-quarter.
- 8 funds opened new Adverum Biotechnologies positions in Q2 2016 and 13 closed out, a net change of -5 holders.
- The largest Adverum Biotechnologies buyer in Q2 2016 was Renaissance Technologies, an estimated $2.06M added.
- The largest Adverum Biotechnologies seller in Q2 2016 was Great Point Partners, an estimated $3.37M sold.
Based on aggregated 13F filings for Q2 2016.